CONFIDENTIAL Page 8 of RTCy ruxolitinib 33Acute graftversushost disease treatment 33Dose regimen and modification 34Drug supplies 35Other study treatments 35Concomitant medications 35Permitte ID: 878886
Download Pdf The PPT/PDF document "RTCyRuxo Clinical Trial Protocol draft v..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1 RTCy-Ruxo Clinical Trial Protocol, draft
RTCy-Ruxo Clinical Trial Protocol, draft version 2.0 from 10.10.2019 CONFIDENTIAL Page 8 of RTCy + ruxolitinib ................................................................................... 33Acute graft-versus-host disease treatment ........................................................... 33Dose regimen and modification ........................................................................... 34Drug supplies ....................................................................................................... 35Other study treatments ......................................................................................... 35Concomitant medications ..................................................................................... 35Permitted medications .............................................................................. 35Prohibited medications ............................................................................. 36EFFICACY AND SAFETY ASSESMENTS .................................................................. 37Efficacy assesments ............................................................................................. 38Safety assessments ............................................................................................... 43Adverse events ..................................................................................................... 43Definitions ................................................................................................ 43Seriousness criteria................................................................................... 44Reporting .................................................................................................. 45Pregnancy ................................................................................................. 46DATA ANALYSIS AND STATISTICAL METHODS ................................................. 47DIRECT ACCESS TO SOURCE DATA ........................................................................ 48AUDITS AND INSPECTIONS / QUALITY CONTROL .............................................. 48ETHICAL CONSIDERATIONS ............................
2 ........................................
......................................................... 49Institutional review board / Independent ethics committee ................................. 49Patient information and informed consent ........................................................... 49Confidentiality ..................................................................................................... 49Study discontinuation ........................................................................................... 49Confidentiality ..................................................................................................... 50DATA MANAGEMENT ................................................................................................. 50AUDITS AND INSPECTIONS / QUALITY CONTROL .............................................. 50FINANCIAL ASPECTS AND , 1 6 8 5 $ 1K ( ................................................................ 50STUDY RESULTS AND PUBLICATIONS .................................................................. 50REFERENCES ................................................................................................................. 52APPENDICES ................................................................................................................. 57Appendix 1: Dose adjustment of calcineurin inhibitors ....................................... 57Appendix 2: Clinical manifestations of the cytokine release syndrome and clinical intervention .............................................................................................. 59LIST OF TABLES Table 3-1: Study visits ................................................................................................................. 22Table 3-2: Cryopreservation schedule ......................................................................................... 24Table 5-1: Busulfan 8 mg/kg conditioning regime ...................................................................... 30Table 5-2: Busulfan 10 mg/kg conditioning regime .................................................................... 30 RTCy-Ruxo Clinical Trial Protocol, draft version 2.0 from 10.10.2019 CONFIDENTIAL Page 9 of
3 Table 5-3: Busulfan 12 mg/kg conditionin
Table 5-3: Busulfan 12 mg/kg conditioning regime .................................................................... 30Table 5-4: Busulfan 14 mg/kg conditioning regime .................................................................... 31Table 5-5: Busulfan 16 mg/kg conditioning regime .................................................................... 31Table 6-1: GVHD staging ............................................................................................................ 38Table 6-2: Overall grade and organ involvement grade evaluation ............................................. 39Table 7-1: Sample size ................................................................................................................. 47LIST OF FIGURES Figure 3-1: Study design .............................................................................................................. 20Figure 5-1: Dose regimen and modifications ............................................................................... 35 RTCy-Ruxo Clinical Trial Protocol, draft version 2.0 from 10.10.2019 CONFIDENTIAL Page of LIST OF ABBREVIATIONS Abbreviation Definition AE adverse event ALL acute lymphoblastic leukemia AML acute myeloid leukemia CMV cytomegalovirus CNI calcineurin inhibitors CRS cytokine release syndrome CTCAE Common Terminology Criteria for Adverse Events DNA deoxyribonucleic acid EFS event-free survival GVHD © J U D I W-versus- K R V W ª G L V H D V H GVL © J U D I W-versus- O H X N H P L D ª H I I H F W HSCT allogeneic hematopoietic stem cell transplantation IMP investigational medical product MMF mycophenolate mofetil NRM non-relapse mortality PTCy post-transplant cyclophosphamide RNA ribonucleic acid SAE serious adverse event RTCy-Ruxo Clinical Trial Protocol, draft version 2.0 from 10.10.2019 CONFIDENTIAL Page of GLOSSARY OF TERMS Term Definition $ F X W H © J U D I W-versus- K R V W ª G L V H D V H Develops from the time the transplant is engrafted and up to 100 days after transplantation &